Opendata, web and dolomites

M6AQuantKit SIGNED

Development and commercialization of kit for quantitative interrogation of a key RNA modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 M6AQuantKit project word cloud

Explore the words cloud of the M6AQuantKit project. It provides you a very rough idea of what is the project "M6AQuantKit" about.

input    cancer    methodology    amounts    n6    carcinoma    functions    unmet    material    strategy    interrogation    seq    market    business    considerations    therapeutic    sensitive    commercialization    renewal    self    implicated    cancers    quantifying    regulation    dysregulation    glioblastoma    cell    multiplexed    industries    samples    therapeutics    variety    unravelling    diseases    coupled    streamlined    commercializable    erc    ip    scientific    benefit    position    leukemia    added    patient    relying    readout    drug    hepatocellular    rnase    monitoring    create    methylation    kit    data    mazter    representing    harnesses    immense    metabolism    quantitative    methyladenosine    poc    tool    protocol    amenable    metastasis    community    multiple    raised    vast    roles    prioritizing    pharma    simultaneous    seeking    labs    startup    consequently    feedback    interrogating    machinery    human    planning    m6a    diagnostic    consistently    exhibits    fundamental    plays    levels    stem    systematic    biotech    rna    academic    actions    first    disease    ribonuclease    profiling    industry   

Project "M6AQuantKit" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

N6-Methyladenosine (m6A) plays fundamental roles in regulation of metabolism, stem cell self-renewal, and metastasis. Consistently its dysregulation is implicated in a variety of human cancers including leukemia, glioblastoma and hepatocellular carcinoma. Consequently, the potential of m6A both as a novel cancer diagnostic and as a drug target has raised immense interest in scientific community and industry. For unravelling m6A functions, for the development of therapeutics and for prioritizing diseases and disease states most likely to benefit from therapeutic targeting of the methylation complex, it is thus of crucial importance to be able to measure the levels at which m6A is present. In our ERC project we addressed this challenge and developed MAZTER-seq, a methodology for quantifying m6A levels relying on a methylation-sensitive ribonuclease (RNase), representing the first systematic approach for quantitative interrogating of m6A levels.

The goal of the project is to advance our approach as commercializable kit for quantitative profiling of m6A. In the PoC, we will develop multiplexed protocol of MAZTER-seq that allows the simultaneous processing and interrogation of multiple samples from low amounts of sample material. The kit, coupled with streamlined data analysis tool, addresses a major market need and exhibits significant added value for academic labs and the biotech & pharma industries targeting the methylation machinery, e.g. for creating novel RNA based therapeutics. Our readout from low-input material makes m6A monitoring amenable to patient samples, representing an unmet challenge across all our target market. Thus, our goal is to create a startup which harnesses the vast market potential. In the PoC, the commercialization considerations are advanced through actions such as, seeking market feedback, strengthening the IP position, defining the business strategy and planning business execution.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "M6AQUANTKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "M6AQUANTKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EVOCELFATE (2019)

Evolution of cell fate specification modes in spiral cleavage

Read More  

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More  

BALANCE (2019)

Mapping Dispersion Spectroscopically in Large Gas-Phase Molecular Ions

Read More